Inhibition of DNA-PK by gefitinib causes synergism between gefitinib and cisplatin in NSCLC

Lung cancer has the highest incidence and mortality rates among the malignant tumor types world-wide. Platinum-based chemotherapy is the main treatment for advanced non-small-cell lung cancer (NSCLC), and epidermal growth factor receptor-tyrosine kinase inhibitors (EGFR-TKIs) have greatly improved t...

Deskribapen osoa

Gorde:
Xehetasun bibliografikoak
Argitaratua izan da:Int J Oncol
Egile Nagusiak: Pan, Chi, Duan, Huijie, Wu, Yinan, Zhu, Chunpeng, Yi, Chenghao, Duan, Yin, Lu, Demin, Guo, Cheng, Wu, Deqi, Wang, Yanyan, Fu, Xianhua, Xu, Jing, Chen, Yiding, Luo, Meng, Tian, Wei, Pan, Tao, Xu, Wenhong, Zhang, Suzhan, Huang, Jianjin
Formatua: Artigo
Hizkuntza:Inglês
Argitaratua: D.A. Spandidos 2020
Gaiak:
Articles
Sarrera elektronikoa:https://ncbi.nlm.nih.gov/pmc/articles/PMC7473755/
https://ncbi.nlm.nih.gov/pubmed/32945394
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3892/ijo.2020.5103
Etiketak: Etiketa erantsi
Etiketarik gabe, Izan zaitez lehena erregistro honi etiketa jartzen!

Antzeko izenburuak